We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .
Piretanide in the treatment of essential hypertension. A double-blind comparison versus placebo.
In a r and omized , double-blind parallel group study the 24-hour hypotensive effect of piretanide and its influence on biochemical variables were compared with those of placebo in patients with mild to moderate essential hypertension . Sixty patients entered the study , all of whom met the inclusion criteria ( RRdiast between 95 and 120 mmHg ) . There was no drop-out during the study , so that the results of all 60 patients were statistically analysed . Piretanide produced a significant reduction of both systolic and diastolic blood pressure over 24 hours which was evident at four weeks and was maintained and further enhanced over the ensuing trial period . A mean maximal fall ( at 12 weeks ) of 10.7 % ( BPdiast supine ) was observed . Placebo tablets did not produce any clinical ly relevant changes in systolic blood pressure , whereas a slight decrease was seen in diastolic blood pressure . This blood pressure reduction was significantly less in the placebo group than in the piretanide group at the end of the study ( weeks 10 and 12 ) . Dose doubling was needed in 13 of the 30 patients in the piretanide group , whereas as many as 20 out of 30 patients needed dose doubling in the placebo group . Pulse rate did not change relevantly during the trial in either group . A slight reduction in body weight was observed in the piretanide group . The mean values of serum potassium and sodium showed a slight decrease but remained within the normal range during the study period . A small increase in serum phosphorus was noted . None of these changes required any specific measures . ( ABSTRACT TRUNCATED AT 250 WORDS
We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .